Taglich Brothers Initiates Coverage on BioCurex, Inc.

NEW YORK, NY--(Marketwire - August 30, 2010) -  Taglich Brothers, Inc. announces it initiated coverage of BioCurex, Inc.

BioCurex, Inc. (OTCBB: BOCX), based in Richmond, British Columbia, Canada, is a development stage company. BioCurex has developed a broad-spectrum cancer blood test that could potentially detect several major cancers with greater accuracy than existing tests for widely used tumor markers. The company's blood test is based on a new proprietary cancer marker named RECAF, which is found on most cancer cells, including breast, colon, prostate and lung cancers, but not on normal cells.

RECAF technology is covered by patents granted in the US, Europe and China and pending in other major markets.

The RECAF blood test can be formatted for use on automated instrumentation typically found in reference laboratories on in hospital laboratories. It can also be formatted for manual (individual or small-batch) tests or as a point-of-care (POC) single use rapid test for use in physicians' offices, urgent care facilities and at the bedside.

BioCurex is pursuing a dual track commercialization strategy. For development of RECAF tests on blood samples processed in automatic equipment in reference and large hospital laboratories, the company has granted Abbott Laboratories and Alere (formerly Inverness Innovative Medical) semi-exclusive licenses. The company is allowed to grant a third semi-exclusive license for automated testing.

Through its own efforts, the company aims to develop and commercialize RECAF manual tests not processed on automatic equipment, POC rapid tests for the physicians' office, including all other single-format potential uses and all tests for veterinary applications.

The complete 21-page report is available at www.taglichbrothers.com.

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.

All research issued by Taglich Brothers, Inc. is based on public information. In July 2010, the company paid US$6,000.00 representing payment in advance for the creation and dissemination of research reports for three months. The company will pay a total of US$24,000.00 for a minimum of twelve (12) months of such services. 

For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.

Contact Information:

Contact:
Richard Oh
Taglich Brothers, Inc.
631-757-1500